Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
Slideset - This single-arm phase II study demonstrated enhanced cell cycle arrest with the addition of palbociclib to neoadjuvant anastrozole in patients with ER+/HER2- early breast cancer.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Neoadjuvant Therapy | Study